

1. Record Nr.	UNISA990002904880203316
Autore	BLUM, Rudolf
Titolo	Bibliografia : indagine diacronica sul termine e sul concetto / Rudolf Blum ; nota introduttiva di Attilio Mauro Caproni
Pubbl/distr/stampa	Milano : Sylvestre Bonnard, 2007
ISBN	978-88-89609-26-2
Descrizione fisica	258 p. ; 22 cm
Collana	Studi bibliografici
Disciplina	010.9
Soggetti	Bibliografia - Storia
Collocazione	I.2.A. 118 I.2.A. 118a L.P. 108 (c/o Direzione)
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Traduzione di Maria Letizia Fabbrini

2. Record Nr.	UNINA9910150529103321
Autore	Kim Kyu-Won
Titolo	Cancer Drug Discovery : Science and History // by Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim
Pubbl/distr/stampa	Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2016
ISBN	94-024-0844-4
Edizione	[1st ed. 2016.]
Descrizione fisica	1 online resource (XVII, 276 p. 138 illus., 134 illus. in color.)
Disciplina	614.5999
Soggetti	Cancer - Research Pharmacy Medicine—History Cancer Research History of Medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references at the end of each chapters.
Nota di contenuto	Part . A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part . Cancer Drug Discovery – Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1A historical background of cancer chemotherapy -- 3.2Development of the anticancer drug screening systems -- 3.3Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1Plant-derived anticancer drugs -- 6.2Anticancer antibiotics -- 7.Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal

anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part . A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.

---

## Sommario/riassunto

This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer.

---